期刊文献+

雷洛昔芬对去卵巢大鼠纤维蛋白原的影响

The Effect of Raloxifene on Fibrinogen in Ovariectomized Rats
暂未订购
导出
摘要 目的探讨选择性雌激素受体调节剂雷洛昔芬对去卵巢大鼠血浆纤维蛋白原的影响。方法40只12周龄雌性SD大鼠随机分为5组,每组8只。(1)去卵巢组(Ovariectomy,OVX):切除大鼠双侧卵巢建立绝经后模型,给予等量生理盐水灌胃;(2)假手术对照组(Control,C):只打开腹腔未切除双侧卵巢,给予等量生理盐水灌胃;(3)雌激素组(Ovariectomy+Estrogen,E):切除大鼠双侧卵巢,给予雌激素(倍美力,1mg/kg·d)灌胃治疗;(4)小剂量雷洛昔芬组(Ovariectomy+Raloxifene,Rs):切除大鼠双侧卵巢,给予雷洛昔芬(易维特,1mg/kg·d)灌胃治疗;(5)大剂量雷洛昔芬组(Ovariectomy+Raloxifene,Rl):切除大鼠双侧卵巢,给予雷洛昔芬([易维特,3mg(/kg·d)灌胃治疗。治疗3个月后,测量治疗后各组血浆纤维蛋白原的变化。结果去卵巢组血清雌二醇水平明显下降,显著低于假手术对照组。雌激素或雷洛昔芬治疗后血清雌二醇水平都上升,接近假手术对照组(OVX:36.69±6.91比C:248.32±32.51比E:240.89±29.44比Rs:239.56±25.73比Rl:243.48±27.62pg/mL,P<0.01)。去卵巢组的血浆纤维蛋白原浓度显著高于假手术对照组和雷洛昔芬组。雌激素组纤维蛋白原的浓度也升高,与假手术对照组比较有统计学意义。雷洛昔芬治疗后纤维蛋白原下降,低于去卵巢组和雌激素组(OVX:4.25±0.43比C:1.76±0.20比E:3.46±0.31比Rs:1.63±0.19比Rl:1.41±0.16g/L,P<0.05)。结论雌性SD大鼠双侧卵巢切除后,纤维蛋白原水平升高。雌激素治疗不能降低纤维蛋白原水平反而升高其水平,而雷洛昔芬能降低纤维蛋白原水平。 Objective To investigate the effect of raloxifene,a selective estrogen receptor modulator,on fibrinogen in ovariectomized rats. Methods Forty twelve-week-old female Spragne-Dawley rats were randomly divided into five groups:( 1 )ovariectomy(OVX);(2)sham operation(C ) ; (3)ovariectomy + estrogen[( 1mg/(kg·d), E]; (4)ovariectomy + small dose raloxifene[1mg/(kg·d), Rs]; (5)ovariectomy + large dose raloxifene[3mg/(kg·d),Rl]. Serum estradiol and fibrinogen were measured before and after three-month treatment. Results Serum estradiol concentration was significantly lower in ovarieetomized rats than that in sham operated animals. Serum estradiol was increased after the treat- ment of raloxifene(OVX:36.69 ± 6.91 vs C:248.32 ± 32.51 vs E:240.89 ± 29.44 vs Rs:239.56 ± 25.73 vs Rl:243.48 ± 27.62 pg/ml,P〈 0.01 ). The concentration of serum fibrinogen(Fg)was increased in OVX and E groups,raloxifene could decreased Fg(OVX:4.25 ± 0.43 vs C: 1.76 ± 0.20 vs E:3.46 ± 0.31 vs Rs: 1.63 ± 0.19 vs Rl: 1.41 ± 0.16g/L,P〈 0.05). Conclusion The concentration of serum fibrinogen increased after ovariectomy, raloxifene could decreased fibrinogen.
出处 《中国现代医生》 2008年第29期1-3,共3页 China Modern Doctor
关键词 雷洛昔芬 雌激素 受体 血压 大鼠 Raloxifene Estrogen Receptor Lipid Rat
  • 相关文献

参考文献13

  • 1[1]Bryant HU,Dere WH.Selective estrogen receptor modulatcn:an altema five to hormone replacent thmpy[J]Proc Soc Exp Bio Med,1998,217(1):45-52.
  • 2[2]Lain PM,Chung TK,Haines C.Where are we with postmenopausal bormone therapy in 20057[J].Gyencol Endeerinol,2005,21(5):248-256.
  • 3陈小明,吴可贵.雷洛昔芬对心血管的保护作用[J].中国药房,2006,17(17):1346-1348. 被引量:5
  • 4[4]Fuchs YR,Glasebrook AL,Short LL.et al.Raloxifene is a tissue-selective agonist/antagonist that functions thigh the estrogen teceptor[J] Ann NY Acad sci,1995,761(12):355-360.
  • 5张廷星,晋学庆,吴可贵,许昌声,陈小明.雌激素对SD大鼠血脂代谢的影响[J].高血压杂志,2005,13(12):797-799. 被引量:8
  • 6[6]Callejo J,Cano A,Medina M,et al Hormonal environment in the induction of breast cancer in castrated tats using dimethylheaumthracene:influence of the presence or absence of ovarian activity and of treatment with estradiol,tibolone,and raloxifene[J].Menopause,2005,12(5):601-608.
  • 7[7]Barrett-Connor E,Grady D,Sashegi A,et al.Raloxifeae and cardiovascular events in osteoporotic postmenopausal women.Four-year results from the MORE(Multiple Outcomes of Raloxifene Eveluation)Randomized Trial[J].JAMA,2002,287(7):847-857.
  • 8[8]Mobasseri S,Liebeon PR,Klein LW.Hormone therapy end selective estrogen receptor modulators for prevention of coronary heart disease in postmenopausal women[J].Cardiology in Review,2004,12(6):287-298.
  • 9吴大方,周泉,周岩,刘秦元,丁宝玲.绝经后妇女雌激素水平与血糖及血脂变化的关系[J].中国综合临床,2005,21(1):31-32. 被引量:29
  • 10[10]Ann NY Aead Sci.The effects of estrogen and selective receptor modulators on cardiovascular risk factors[J].2001,949(12):163-167.

二级参考文献42

  • 1唐细兰,王延东.植物雌激素对心血管系统的保护作用[J].中国药房,2005,16(18):1423-1424. 被引量:1
  • 2张廷星,晋学庆,吴可贵,许昌声,陈小明.雌激素对SD大鼠血脂代谢的影响[J].高血压杂志,2005,13(12):797-799. 被引量:8
  • 3Diamond MP, Grainger D, Diamond MC, et al. Effects of methyltestosterone on insulin secretion and sensitivity in women [ J ]. J Clin Endocrionl Metab,1998,83(12) :4420.
  • 4Ambrus CM,Ambrus JL.Hormone-replacement therapy and coagulation[J].Nengl J Med,1997,17,337:200-201.
  • 5Stomati M,Bernardi F,Luisi S,et al.Conjugated equine estrogens,estrone sulphate and estradiol valerate oral administration in ovariectomized rats:effects on central and peripheral allopregnenolone and β-endorphin[J].Maturitas,2002,20,43:195-206.
  • 6Oakley CM,Overview.Hypertension in postmenopauseal women.270 Madison Avenue[M]//New York,Marcel Dekker,Inc.1996,1-11.
  • 7Lip GY,Zarifis J,Beevers G.Concurrent risk factors.Hypertension in Postmenopauseal Women.270 Madison Avenue[M]//New York.Marcel Dekker,Inc.1996,113-138.
  • 8Ravinkar V,Kramer-Coutinho B.Lipids,hormone replacement therapy,and diet.Hypertension in Postmenopauseal Women.270 Madison Avenue[M]//New York,Marcel Dekker,Inc.1996,149-172.
  • 9Hulley S,Grady D,Bush T,et al.Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women[J].JAMA,1998,19,280:605-613.
  • 10Nabulsi AA,Folsom AR,White A,et al.Association of hormone-replacement therapy with various cardiovascular risk factors in postmenopausal women[J].N Engl J Med,1993,328:1069-1075.

共引文献39

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部